Canada - English - Health Canada

novartis pharmaceuticals canada inc - inclisiran (inclisiran sodium) - solution - 284mg - inclisiran (inclisiran sodium) 284mg

Israel - English - Ministry of Health

novartis israel ltd - inclisiran as sodium - solution for injection - inclisiran as sodium 189 mg/ml - inclisiran - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:• in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl c goals with the maximum tolerated dose of a statin, or• alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage); nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) - powder for injection with diluent - 1000 iu - active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 1000 [iu] (actually contains 1100 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage); nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) - powder for injection with diluent - 250 iu - active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection sodium chloride water for injection active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage); nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) - powder for injection with diluent - 500 iu - active: nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection active: nonacog alfa 500 [iu] (actually contains 550 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - powder for solution for infusion - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, clostridium perfringens, and peptostreptococcus micros.community-acquired bacterial pneumonia:community-acquired bacterial pneumonia caused by streptococcus pneumoniae (penicillin susceptible isolates), including cases with concurrent bacteremia, haemophilus influenzae (beta-lactamase negative isolates), and legionella pneumophila.

Ireland - English - HPRA (Health Products Regulatory Authority)

cis bio international - rhenium sulphide - kit for radiopharmaceutical preparation - milligram - technetium (99mtc), particles and colloids

Ireland - English - HPRA (Health Products Regulatory Authority)

cis bio international - sodium oxidronate - kit for radiopharmaceutical preparation - 3.0 milligram(s) - technetium (99mtc) compounds; technetium (99mtc) oxidronic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

cis bio international - dimercaptosuccinic acid - kit for radiopharmaceutical preparation - 1 mg - technetium (99mtc) compounds; technetium (99mtc) succimer

Ireland - English - HPRA (Health Products Regulatory Authority)

cis bio international - tetrakis (2-methoxy isobutyl isonitrile) copper (i) tetrafluorolborate - kit for radiopharmaceutical preparation - 1 milligram(s) - technetium (99mtc) compounds; technetium (99mtc) sestamibi